tradingkey.logo

Sanara Medtech Inc

SMTI
查看详细走势图
25.040USD
+0.830+3.43%
收盘 12/22, 16:00美东报价延迟15分钟
223.63M总市值
亏损市盈率 TTM

Sanara Medtech Inc

25.040
+0.830+3.43%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+3.43%

5天

+1.38%

1月

+28.54%

6月

-8.21%

今年开始到现在

-24.58%

1年

-25.65%

查看详细走势图

TradingKey Sanara Medtech Inc股票评分

单位: USD 更新时间: 2025-12-19

操作建议

Sanara Medtech Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名70/158位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价41.00。中期看,股价处于下降通道。近一个月,市场表现很强,技术面和基本面综合得分较高,很强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

Sanara Medtech Inc评分

相关信息

行业排名
70 / 158
全市场排名
175 / 4582
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 2 位分析师
买入
评级
41.000
目标均价
+88.42%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Sanara Medtech Inc亮点

亮点风险
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
业绩高增长
公司营业收入稳步增长,连续3年增长89.06%
业绩增长期
公司处于发展阶段,最新年度总收入86.67M美元
利润高增长
公司净利润处于行业前列,最新年度总收入86.67M美元
估值高估
公司最新PE估值-5.56,处于3年历史高位
机构减仓
最新机构持股1.11M股,环比减少1.70%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值41.70K

Sanara Medtech Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Sanara Medtech Inc简介

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
公司代码SMTI
公司Sanara Medtech Inc
CEOMuppalla (Suresh V)
网址https://sanaramedtech.com/

常见问题

Sanara Medtech Inc(SMTI)的当前股价是多少?

Sanara Medtech Inc(SMTI)的当前股价是 25.040。

Sanara Medtech Inc的股票代码是什么?

Sanara Medtech Inc的股票代码是SMTI。

Sanara Medtech Inc股票的52周最高点是多少?

Sanara Medtech Inc股票的52周最高点是38.680。

Sanara Medtech Inc股票的52周最低点是多少?

Sanara Medtech Inc股票的52周最低点是18.900。

Sanara Medtech Inc的市值是多少?

Sanara Medtech Inc的市值是223.63M。

Sanara Medtech Inc的净利润是多少?

Sanara Medtech Inc的净利润为-9.66M。

现在Sanara Medtech Inc(SMTI)的股票是买入、持有还是卖出?

根据分析师评级,Sanara Medtech Inc(SMTI)的总体评级为买入,目标价格为41.000。

Sanara Medtech Inc(SMTI)股票的每股收益(EPS TTM)是多少

Sanara Medtech Inc(SMTI)股票的每股收益(EPS TTM)是-4.355。
KeyAI